COMPASS Pathways News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.11.21	COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021 (GlobeNewswire)
09.11.21	COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression (GlobeNewswire)
03.11.21	COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder (GlobeNewswire)
20.10.21	Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups (GlobeNewswire)
19.10.21	COMPASS Pathways is granted new US patent for crystalline psilocybin (GlobeNewswire)
14.09.21	COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs (GlobeNewswire)
10.09.21	Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds (GlobeNewswire)
11.08.21	COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021 (GlobeNewswire)
29.07.21	Guy Goodwin joins COMPASS Pathways as Chief Medical Officer (GlobeNewswire)
21.07.21	Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training (GlobeNewswire)
05.07.21	COMPASS Pathways joins forces with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research and develop new models of mental health care in the UK (GlobeNewswire)
30.06.21	COMPASS Pathways launches new podcast “Everyone has a story: talking about mental health” (GlobeNewswire)
28.06.21	COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression (GlobeNewswire)
23.06.21	COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme (GlobeNewswire)
03.06.21	COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers (GlobeNewswire)
13.05.21	COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021 (GlobeNewswire)
30.04.21	COMPASS Pathways announces pricing of public offering (GlobeNewswire)
27.04.21	COMPASS Pathways launches proposed public offering (GlobeNewswire)
15.04.21	New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder (GlobeNewswire)
09.04.21	COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
01.04.21	COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors (GlobeNewswire)
23.03.21	COMPASS Pathways granted two US patents (GlobeNewswire)
09.03.21	COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020 (GlobeNewswire)
09.02.21	COMPASS Pathways expands its Discovery Center through new collaborations with world-leading scientists (GlobeNewswire)
03.02.21	COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy (GlobeNewswire)
08.01.21	COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care (GlobeNewswire)
12.11.20	COMPASS Pathways plc announces financial results for third quarter 2020 (GlobeNewswire)
09.11.20	COMPASS Pathways joins the Psychiatry Consortium in a collaboration to accelerate drug discovery in mental health care (GlobeNewswire)
29.09.20	GNFT Soars On LabCorp Deal, INO's COVID-19 Vaccine Trial On Partial Hold, FDA Expands Xeljanz Label (RTTNews)
18.09.20	COMPASS Pathways Prices Upsized IPO At $17/Shr, Above Expected Range (RTTNews)
16.09.20	This Week's Healthcare IPOs (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Part Grp Hldg	1’260.00	2.61 %	K V
Sonova Hldg	311.20	2.37 %	K V
Novartis	93.63	2.26 %	K V
Geberit	525.00	1.63 %	K V
Roche Hldg G	255.00	1.55 %	K V
Swiss Life Hldg	732.00	0.66 %	K V
UBS Group	28.28	0.50 %	K V
Swisscom	507.00	0.30 %	K V
Nestle	76.14	0.24 %	K V
Kuehne+Nagel Int	208.20	0.10 %	K V

Nachrichten zu COMPASS Pathways PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten